

Supporting Information

An Efficient Passerini Tetrazole Reaction (PT-3CR)

Ajay L. Chandgude, Alexander Dömling

Contents

General Information.....	3
Experimental Procedures and Spectral Data.....	4
Procedure for the synthesis of 5,11-dihydrobenzo[<i>f</i>]tetrazolo[5,1- <i>c</i>][1,4]oxazepine.....	11
NMR spectra and SFC-MS Chromatograms	12

General Information

Reagents were available from commercial suppliers (Sigma Aldrich, ABCR, Acros and AK Scientific) and used without any purification unless otherwise noted. Thin layer chromatography was performed on Fluka precoated silica gel plates (0.20 mm thick, particle size 25 μm). Flash chromatography was performed on a Teledyne ISCO CombiFlash Rf, using RediSep Rf Normal-phase Silica Flash Columns (Silica Gel 60 Å, 230 - 400 mesh) and on a Reveleris® X2 Flash Chromatography, using Grace® Reveleris Silica flash cartridges (12 grams). All ultrasonic irradiation reactions were carried out in a Sonicor “SC” Ultrasonic Table Top Cleaner with 220/240V, frequency of 50/60 Hz and 25 Amps. Nuclear magnetic resonance spectra were recorded on a Bruker Avance 500 spectrometer. Chemical shifts for ^1H NMR were reported relative to TMS (δ 0 ppm) and coupling constants were in hertz (Hz). The following abbreviations were used for spin multiplicity: s = singlet, d = doublet, t = triplet, dt = double triplet, ddd = doublet of double doublet, and m = multiplet. Chemical shifts for ^{13}C NMR reported in ppm relative to the solvent peak (CDCl_3 δ 77.23 ppm). Mass spectra were measured on a Waters Investigator Supercritical Fluid Chromatograph with a 3100 MS Detector (ESI) using a solvent system of methanol and CO_2 on a Viridis silica gel column (4.6 \times 250 mm, 5 μm particle size) and reported as (m/z).


Experimental Procedures and Spectral Data

General procedure for the synthesis of tetrazole:

A 10 ml tube was charged with aldehyde/ketone (1.0 mmol) and isocyanide (1.0 mmol) and trimethylsilyl azide (1 mmol) in methanol:water (1:1) (1 ml). The mixture was sonicated in the water bath of an ultrasonic cleaner (220/240V, 25 Amps and frequency of 50/60 Hz) at room temperature till completion of the reaction (monitored by TLC). The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography using EtOAc–hexane as eluent.


Spectral Data

1-(1-benzyl-1*H*-tetrazol-5-yl)-2-phenylethanol (3a)




Colourless liquid, mp 79–80 °C, yield: 268 mg (96%); ^1H NMR (500 MHz, CDCl_3) δ 7.34 – 7.29 (m, 3H), 7.29 – 7.23 (m, 3H), 7.18 (dd, J = 6.6, 2.9, 2H), 7.11 – 7.04 (m, 2H), 5.49 (d, J = 15.1, 1H), 5.37 (d, J = 15.1, 1H), 5.25 – 5.09 (m, 1H), 3.39 (s, 1H), 3.19 (dd, J = 13.8, 5.4, 1H), 3.07 (dd, J = 13.8, 8.3, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 155.9, 135.8, 133.8, 129.6, 129.0, 128.8, 128.7, 128.0, 127.2, 66.2, 51.3, 42.3. MS (ESI) m/z calculated [M+H] $^+$: 281.13; found [M+H] $^+$: 281.16.

1-(1-(*tert*-butyl)-1*H*-tetrazol-5-yl)-2-methylpropan-1-ol (3b)



White solid, mp 126–127 °C, yield: 195 mg (98%); ^1H NMR (500 MHz, CDCl_3) δ 4.71 (dd, J = 10.2, 8.5, 1H), 3.23 (d, J = 10.1, 1H), 2.53 – 2.39 (m, 1H), 1.78 (s, 9H), 1.18 (d, J = 6.6, 3H), 0.85 (d, J = 6.7, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 156.3, 70.8, 61.6, 34.1, 30.3, 19.5, 18.2. MS (ESI) m/z calculated [M+Na] $^+$: 221.14; found [M+Na] $^+$: 221.18.


1-(1-benzyl-1*H*-tetrazol-5-yl)butan-1-ol (3c)



Colourless liquid, yield: 186 mg (80%); ^1H NMR (500 MHz, CDCl_3) δ 7.41 – 7.31 (m, 3H), 7.31 – 7.24 (m, 2H), 5.72 (q, J = 15.1, 2H), 4.99 (t, J = 6.4, 1H), 3.98 (s, 1H), 1.92 – 1.78 (m, 1H), 1.77 – 1.67 (m, 1H).


(m, 1H), 1.49 – 1.36 (m, 1H), 1.30 – 1.24 (m, 1H), 0.84 (t, $J = 7.4$, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 156.5, 133.9, 129.0, 128.7, 127.9, 64.7, 51.5, 37.6, 18.4, 13.5. MS (ESI) m/z calculated [M+Na] $^+$: 255.12; found [M+Na] $^+$: 255.08.

2-phenyl-1-(1-(2,4,4-trimethylpentan-2-yl)-1*H*-tetrazol-5-yl)ethanol (3d)




White solid, mp 135–136 °C, yield: 232 mg (77%); ^1H NMR (500 MHz, CDCl_3) δ 7.27 – 7.22 (m, 2H), 7.21 – 7.16 (m, 3H), 5.38 – 5.20 (m, 1H), 4.09 (d, $J = 9.6$, 1H), 3.48 (qd, $J = 13.4$, 7.2, 2H), 1.96 (d, $J = 15.2$, 1H), 1.81 (d, $J = 17.6$, 4H), 1.57 (s, 3H), 0.68 (s, 9H). ^{13}C NMR (126 MHz, CDCl_3) δ 156.3, 136.2, 129.7, 128.7, 127.1, 67.1, 65.3, 53.8, 43.2, 31.6, 30.5, 30.3, 30.2. MS (ESI) m/z calculated [M+Na] $^+$: 325.20; found [M+Na] $^+$: 325.20.

3-(5-(1-hydroxy-2-methylpropyl)-1*H*-tetrazol-1-yl)propanenitrile (3e)




Colorless liquid, yield: 140 mg (72%); ^1H NMR (500 MHz, CDCl_3) δ 4.92 (dt, $J = 13.9$, 6.9, 2H), 4.77 (dt, $J = 13.7$, 6.8, 1H), 4.30 (s, 1H), 3.12 (t, $J = 6.9$, 2H), 2.29 – 2.16 (m, 1H), 1.08 (d, $J = 6.7$, 3H), 0.91 (d, $J = 6.8$, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 156.1, 116.3, 70.9, 43.7, 33.8, 18.7, 18.6, 17.8. MS (ESI) m/z calculated [M+Na] $^+$: 218.10; found [M+Na] $^+$: 218.09.

1-(1-(2,2-diethoxyethyl)-1*H*-tetrazol-5-yl)-3-phenylpropan-1-ol (3f)




Colorless liquid, yield: 170 mg (53%); ^1H NMR (500 MHz, CDCl_3) δ 7.37 – 7.24 (m, 2H), 7.23 – 7.12 (m, 3H), 5.04 (dd, $J = 12.8$, 6.4, 1H), 4.82 (t, $J = 5.5$, 1H), 4.63 (dd, $J = 14.2$, 5.6, 1H), 4.52 (dd, $J = 14.2$, 5.4, 1H), 4.08 (d, $J = 5.8$, 1H), 3.85 – 3.66 (m, 2H), 3.59 – 3.38 (m, 2H), 2.93 – 2.72 (m, 2H), 2.44 – 2.24 (m, 2H), 1.12 (dt, $J = 14.3$, 7.0, 6H). ^{13}C NMR (126 MHz, CDCl_3) δ 157.0, 140.7, 128.5, 128.5, 126.1, 100.5, 64.3, 64.2, 64.0, 50.0, 36.9, 31.2, 15.0, 15.0. MS (ESI) m/z calculated [M+H] $^+$: 321.18; found [M+H] $^+$: 321.05.

1-(1-cyclohexyl-1*H*-tetrazol-5-yl)-3-phenylpropan-1-ol (3g)




White solid, mp 104-105 °C, yield: 217 mg (76%); ¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.23 (m, 2H), 7.21 – 7.14 (m, 3H), 5.08 – 4.93 (m, 2H), 4.57 – 4.39 (m, 1H), 2.92 – 2.80 (m, 1H), 2.79 – 2.68 (m, 1H), 2.41 – 2.26 (m, 1H), 2.26 – 2.10 (m, 1H), 2.05 – 1.82 (m, 6H), 1.71 (d, *J* = 12.4, 1H), 1.48 – 1.17 (m, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 155.6, 140.7, 128.6, 128.5, 126.2, 63.7, 58.4, 37.4, 33.0, 31.5, 25.3, 25.2, 24.9. MS (ESI) m/z calculated [M+H]⁺: 287.18; found [M+H]⁺: 287.21.

1-(1-(2-bromobenzyl)-1*H*-tetrazol-5-yl)-2-phenylethan-1-ol (3h)




White solid, mp 94-95 °C, yield: 275 mg (77%); ¹H NMR (500 MHz, CDCl₃) δ 7.55 (dd, *J* = 7.5, 1.6, 1H), 7.29 – 7.21 (m, 3H), 7.17 (td, *J* = 7.1, 1.8, 2H), 7.09 (dd, *J* = 7.5, 1.6, 2H), 6.72 (dd, *J* = 7.3, 1.9, 1H), 5.49 (d, *J* = 16.0, 1H), 5.41 (d, *J* = 16.0, 1H), 5.26 (t, *J* = 6.7, 1H), 4.05 (s, 1H), 3.26 (dd, *J* = 13.7, 5.9, 1H), 3.19 (dd, *J* = 13.7, 7.7, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 156.2, 135.6, 133.3, 133.1, 130.1, 129.6, 129.1, 128.8, 128.1, 127.3, 122.7, 66.2, 51.1, 42.5. MS (ESI) m/z calculated [M+H]⁺: 359.04; found [M+H]⁺: 359.04.

(1-(2-bromobenzyl)-1*H*-tetrazol-5-yl)methanol (3i)




White solid, mp 64-65 °C, yield: 112 mg (42%); ¹H NMR (500 MHz, CDCl₃) δ 7.58 (dd, *J* = 7.9, 1.1, 1H), 7.28 (td, *J* = 7.3, 1.1, 1H), 7.21 (td, *J* = 7.7, 1.6, 1H), 7.04 (dd, *J* = 7.7, 1.5, 1H), 5.73 (s, 2H), 5.13 (s, 1H), 4.94 (s, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 154.5, 133.3, 132.7, 130.5, 129.9, 128.2, 123.2, 53.6, 51.4. MS (ESI) m/z calculated [M+H]⁺: 269.00; found [M+H]⁺: 269.00.

1-(1-(2-bromobenzyl)-1*H*-tetrazol-5-yl)-2-methylpropan-1-ol (3j)




White solid, mp 86-87 °C, yield: 249 mg (80%); ¹H NMR (500 MHz, CDCl₃) δ 7.58 (dd, *J* = 7.8, 0.9, 1H), 7.24 (dt, *J* = 7.6, 3.8, 1H), 7.19 (td, *J* = 7.7, 1.5, 1H), 6.88 (dd, *J* = 7.6, 1.1, 1H), 5.79 (s, 2H), 4.89 – 4.73 (m, 1H), 4.67 (d, *J* = 6.2, 1H), 2.11 (dq, *J* = 13.6, 6.8, 1H), 1.03 (d, *J* = 6.7, 3H), 0.77 (d, *J* = 6.8, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 156.5, 133.5, 133.1, 130.1, 129.2, 128.0, 122.8, 70.3, 51.4, 33.4, 18.7, 18.0. MS (ESI) m/z calculated [M+H]⁺: 311.04; found [M+H]⁺: 311.09.

1-(1-(*tert*-butyl)-1*H*-tetrazol-5-yl)-3-phenylpropan-1-ol (3k)




White solid, mp 102-103 °C, yield: 228 mg (88%); ^1H NMR (500 MHz, CDCl_3) δ 7.32 – 7.26 (m, 2H), 7.20 (d, J = 7.3, 3H), 5.00 (td, J = 9.3, 4.8, 1H), 3.96 (d, J = 9.9, 1H), 3.01 – 2.78 (m, 2H), 2.55 – 2.40 (m, 1H), 2.34 – 2.19 (m, 1H), 1.63 (s, 9H). ^{13}C NMR (126 MHz, CDCl_3) δ 156.5, 140.6, 128.6, 128.5, 126.2, 63.9, 61.7, 38.2, 31.6, 29.9. MS (ESI) m/z calculated [M+H] $^+$: 283.15; found [M+H] $^+$: 283.06.

1-(1-benzyl-1*H*-tetrazol-5-yl)propan-1-ol (3l)




White solid, mp 77-78 °C, yield: 198 mg (91%); ^1H NMR (500 MHz, CDCl_3) δ 7.32 – 7.22 (m, 5H), 5.73 (d, J = 15.1, 1H), 5.68 (d, J = 15.1, 1H), 4.94 (dd, J = 13.3, 6.3, 1H), 4.84 (d, J = 6.2, 1H), 1.94 – 1.73 (m, 2H), 0.87 (t, J = 7.4, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 156.3, 134.0, 129.0, 128.7, 127.9, 66.3, 51.5, 28.9, 9.6. MS (ESI) m/z calculated [M+H] $^+$: 219.12; found [M+H] $^+$: 219.10.

1-(1-benzyl-1*H*-tetrazol-5-yl)-3-methylbutan-1-ol (3m)




White solid, mp 85-86 °C, yield: 226 mg (92%); ^1H NMR (500 MHz, CDCl_3) δ 7.35 – 7.30 (m, 3H), 7.28 – 7.23 (m, 2H), 5.74 (d, J = 15.2, 1H), 5.67 (d, J = 15.1, 1H), 5.15 – 4.95 (m, 1H), 4.55 (d, J = 6.4, 1H), 1.81 – 1.60 (m, 2H), 1.54 – 1.42 (m, 1H), 0.82 (d, J = 6.6, 3H), 0.77 (d, J = 6.5, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 156.7, 133.9, 129.0, 128.7, 127.9, 63.2, 51.5, 44.3, 24.2, 22.8, 21.6. MS (ESI) m/z calculated [M+Na] $^+$: 269.14; found [M+Na] $^+$: 269.13.

1-(1-(*tert*-butyl)-1*H*-tetrazol-5-yl)-2-phenylethanol (3n)




White solid, mp 160-161 °C, yield: 239 mg (97%); ^1H NMR (500 MHz, CDCl_3) δ 7.35 – 7.30 (m, 3H), 7.28 – 7.23 (m, 2H), 5.74 (d, J = 15.2, 1H), 5.67 (d, J = 15.1, 1H), 5.15 – 4.95 (m, 1H), 4.55 (d, J = 6.4, 1H), 1.81 – 1.60 (m, 2H), 1.54 – 1.42 (m, 1H), 0.82 (d, J = 6.6, 3H), 0.77 (d, J = 6.5, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 156.7, 133.9, 129.0, 128.7, 127.9, 63.2, 51.5, 44.3, 24.2, 22.8, 21.6. MS (ESI) m/z calculated [M+Na] $^+$: 269.14; found [M+Na] $^+$: 269.19.

(1-(*tert*-butyl)-1*H*-tetrazol-5-yl)(phenyl)methanol (3o)




White solid, mp 122-123 °C, yield: 95 mg (41%); ^1H NMR (500 MHz, CDCl_3) δ 7.36 (t, $J = 5.8$, 3H), 7.33 – 7.25 (m, 2H), 6.30 (d, $J = 7.3$, 1H), 4.29 (s, 1H), 1.63 (s, 9H). ^{13}C NMR (126 MHz, CDCl_3) δ 155.8, 139.2, 129.0, 128.9, 127.2, 68.5, 62.1, 29.9. MS (ESI) m/z calculated [M+Na] $^+$: 255.12; found [M+Na] $^+$: 255.08.

(1-benzyl-1*H*-tetrazol-5-yl)(2,6-dichlorophenyl)methanol (3p)




White solid, mp 144-145 °C, yield: 237 mg (71%); ^1H NMR (500 MHz, CDCl_3) δ 7.35 – 7.30 (m, 4H), 7.29 (s, 1H), 7.24 (dd, $J = 13.1$, 6.0, 1H), 7.18 (dd, $J = 6.5$, 2.8, 2H), 6.63 (d, $J = 9.3$, 1H), 5.70 (d, $J = 4.5$, 2H), 3.94 (d, $J = 9.4$, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 154.0, 135.2, 133.4, 132.9, 130.9, 129.4, 129.0, 128.7, 127.5, 65.2, 51.8. MS (ESI) m/z calculated [M+H] $^+$: 335.04; found [M+H] $^+$: 335.10.

(1-cyclohexyl-1*H*-tetrazol-5-yl)(2,3-dichlorophenyl)methanol (3q)




White soild, mp 156-157 °C, yield: 238 mg (73%); ^1H NMR (500 MHz, CDCl_3) δ 7.65 (dd, $J = 7.9$, 1.3, 1H), 7.50 (dd, $J = 8.0$, 1.5, 1H), 7.33 (t, $J = 7.9$, 1H), 6.49 (d, $J = 6.2$, 1H), 4.72 (d, $J = 6.3$, 1H), 4.29 (tt, $J = 11.4$, 3.8, 1H), 1.99 – 1.77 (m, 6H), 1.75 – 1.70 (m, 1H), 1.41 – 1.20 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 153.9, 138.3, 133.6, 130.9, 130.6, 127.9, 126.4, 64.2, 58.6, 32.8, 32.7, 25.3, 25.3, 24.8. MS (ESI) m/z calculated [M+H] $^+$: 327.07; found [M+H] $^+$: 327.03.

(5-bromo-2-methoxyphenyl)(1-phenethyl-1*H*-tetrazol-5-yl)methanol (3r)




White soild, mp 133-134 °C, yield: 178 mg (46%); ^1H NMR (500 MHz, CDCl_3) δ 7.47 – 7.40 (m, 2H), 7.35 – 7.27 (m, 3H), 7.04 (dd, $J = 7.6$, 1.4, 2H), 6.76 (d, $J = 9.4$, 1H), 5.85 (d, $J = 7.0$, 1H), 4.56 (t, $J = 7.5$, 2H), 3.86 (d, $J = 7.0$, 1H), 3.70 (s, 3H), 3.18 – 3.01 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.6, 155.3, 136.5, 132.9, 130.5, 129.0, 128.8, 128.1, 127.3, 113.5, 112.8, 63.1, 55.9, 49.2, 36.2. MS (ESI) m/z calculated [M+H] $^+$: 389.03; found [M+H] $^+$: 389.03.

(2-bromophenyl)(1-cyclohexyl-1*H*-tetrazol-5-yl)methanol (3s)




White solid, mp 141–142 °C, yield: 201 mg (60%); ¹H NMR (500 MHz, CDCl₃) δ 7.67 (dd, *J* = 7.8, 1.4, 1H), 7.57 (dd, *J* = 8.0, 0.8, 1H), 7.40 (t, *J* = 7.6, 1H), 7.24 (td, *J* = 7.8, 1.6, 1H), 6.48 (d, *J* = 6.0, 1H), 4.90 (d, *J* = 6.0, 1H), 4.25 (tt, *J* = 11.3, 3.8, 1H), 1.92 – 1.79 (m, 5H), 1.78 – 1.63 (m, 2H), 1.35 – 1.18 (m, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 154.4, 137.5, 133.1, 130.5, 128.8, 128.2, 122.3, 66.0, 58.5, 32.7, 32.7, 25.3, 24.8. MS (ESI) m/z calculated [M+H]⁺: 337.06; found [M+H]⁺: 337.05.

(2-chloro-3,4-dimethoxyphenyl)(1-cyclohexyl-1*H*-tetrazol-5-yl)methanol (3t)




White solid, mp 167–168 °C, yield: 147 mg (42%); ¹H NMR (500 MHz, CDCl₃) δ 7.29 (d, *J* = 8.7, 1H), 6.89 (d, *J* = 8.8, 1H), 6.46 (d, *J* = 6.0, 1H), 4.62 (d, *J* = 6.1, 1H), 4.25 (tt, *J* = 11.5, 3.8, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 1.91 – 1.81 (m, 4H), 1.76 – 1.64 (m, 2H), 1.38 – 1.15 (m, 4H); ¹³C NMR (126 MHz, CDCl₃) δ 154.7, 154.01, 145.5, 128.8, 127.1, 123.5, 110.9, 63.8, 60.7, 58.4, 56.1, 32.7, 32.7, 25.3, 24.8. MS (ESI) m/z calculated [M+H]⁺: 353.13; found [M+H]⁺: 353.05.

(1-cyclohexyl-1*H*-tetrazol-5-yl)(6-nitrobenzo[*d*][1,3]dioxol-5-yl)methanol (3u)



Yellow solid, mp 198–199 °C, yield: 135 mg (39%); ¹H NMR (500 MHz, CDCl₃) δ 7.63 (s, 1H), 7.45 (s, 1H), 6.67 (d, *J* = 5.9, 1H), 6.19 (d, *J* = 11.5, 2H), 4.60 (t, *J* = 11.6, 1H), 4.06 (d, *J* = 5.7, 1H), 2.22 (d, *J* = 12.3, 1H), 2.15 – 1.94 (m, 5H), 1.78 (d, *J* = 12.1, 1H), 1.49 – 1.32 (m, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 153.2, 132.7, 129.8, 108.0, 106.6, 105.9, 105.9, 103.5, 58.5, 33.1, 32.7, 25.3, 24.9. MS (ESI) m/z calculated [M+H]⁺: 348.12; found [M+H]⁺: 348.27.

(1-cyclohexyl-1*H*-tetrazol-5-yl)(2,5-dimethoxyphenyl)methanol (3v)




White solid, mp 189–190 °C, yield: 152 mg (48%); ¹H NMR (500 MHz, CDCl₃) δ 6.93 (d, *J* = 2.2, 1H), 6.86 (d, *J* = 3.1, 2H), 6.34 (d, *J* = 6.5, 1H), 4.35 (tt, *J* = 11.3, 3.7, 1H), 3.98 (d, *J* = 6.7, 1H),

3.75 (s, 6H), 1.94 – 1.83 (m, 4H), 1.80 – 1.67 (m, 2H), 1.40 – 1.19 (m, 4H); ^{13}C NMR (126 MHz, CDCl_3) δ 154.9, 154.0, 150.5, 127.4, 114.89, 113.4, 112.15, 63.4, 58.23, 56.1, 55.8, 32.8, 32.7, 25.4, 24.9. MS (ESI) m/z calculated $[\text{M}+\text{H}]^+$: 319.17; found $[\text{M}+\text{H}]^+$: 319.22.

1-(1-benzyl-1*H*-tetrazol-5-yl)cyclohexanol (3w)

Colorless liquid, yield: 216 mg (84%); ^1H NMR (500 MHz, CDCl_3) δ




7.32 – 7.26 (m, 3H), 7.25 – 7.21 (m, 2H), 5.83 (s, 2H), 3.84 (s, 1H), 1.98 – 1.87 (m, 2H), 1.85 – 1.76 (m, 2H), 1.76 – 1.53 (m, 5H), 1.36 – 1.21 (m, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 159.6, 134.9, 128.8, 128.3, 127.8, 70.45, 52.2, 37.0, 24.9, 21.1. MS (ESI) m/z calculated $[\text{M}+\text{H}]^+$: 259.15;

found $[\text{M}+\text{NH}]^+$: 259.17.


1-benzyl-4-(1-benzyl-1*H*-tetrazol-5-yl)piperidin-4-ol (3x)

Colourless liquid, yield: 160 mg (46%); ^1H NMR (500 MHz, CDCl_3) δ



7.36 – 7.26 (m, 7H), 7.25 – 7.18 (m, 3H), 5.82 (s, 2H), 3.52 (s, 2H), 3.40 (s, 1H), 2.79 – 2.59 (m, 2H), 2.43 (td, $J = 11.6, 2.1, 2\text{H}$), 2.31 – 2.11 (m, 2H), 1.77 (d, $J = 12.8, 2\text{H}$). ^{13}C NMR (126 MHz, CDCl_3) δ 158.8, 138.3, 134.8, 129.0, 128.9, 128.5, 128., 127.6, 127., 68.70, 62., 52., 48., 36.6. MS (ESI) m/z calculated $[\text{M}+\text{H}]^+$: 350.19; found $[\text{M}+\text{H}]^+$: 350.22.

Procedure for the synthesis of 5,11-dihydrobenzo[*f*]tetrazolo[5,1-*c*][1,4]oxazepine




A 10 ml RBF equipped with a magnetic stirring bar was charged with (1-(2-bromobenzyl)-1*H*-tetrazol-5-yl)methanol (0.5 mmol, 134 mg), Copper triflate (20 mol%, 36 mg), N,N'Dimethylethylenediamine (40 mol%, 21 μ l), K₂CO₃ (4 equivalent, 276 mg) in toluene (2ml) and refluxed overnight. Then the reaction mixture was added to a 25 ml saturated NaHCO₃ solution and extracted in ethyl acetate. The solvent was removed under reduced pressure and the mixture was purified by flash chromatography on silica gel (eluent: hexane/EtOAc) to afford the titled compound as a white solid.


5,11-dihydrobenzo[f]tetrazolo[5,1-c][1,4]oxazepine (4)



White solid, yield: 83 mg (89%); ¹H NMR (500 MHz, CDCl₃) δ 7.46 (td, *J* = 7.9, 1.4, 1H), 7.43 – 7.38 (m, 1H), 7.30 (d, *J* = 8.0, 1H), 7.25 (t, *J* = 7.5, 1H), 5.65 (s, 2H), 5.48 (s, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 157.7, 152.1, 131.7, 129.3, 127.8, 126.1, 122.2, 67.6, 49.5. MS (ESI) m/z calculated [M+H]⁺: 189.07; found [M+Na]⁺: 189.10.

NMR spectra and SFC-MS Chromatograms


1-(1-benzyl-1*H*-tetrazol-5-yl)-2-phenylethanol (3a)












1-(1-(*tert*-butyl)-1*H*-tetrazol-5-yl)-2-methylpropan-1-ol (3b)








1-(1-benzyl-1*H*-tetrazol-5-yl)butan-1-ol (3c)








2-phenyl-1-(1-(2,4,4-trimethylpentan-2-yl)-1*H*-tetrazol-5-yl)ethanol (3d)








3-(5-(1-hydroxy-2-methylpropyl)-1*H*-tetrazol-1-yl)propanenitrile (3e)








1-(1-(2,2-diethoxyethyl)-1*H*-tetrazol-5-yl)-3-phenylpropan-1-ol (3f**)**








1-(1-cyclohexyl-1*H*-tetrazol-5-yl)-3-phenylpropan-1-ol (3g)








1-(1-(2-bromobenzyl)-1*H*-tetrazol-5-yl)-2-phenylethanol (3h)








(1-(2-bromobenzyl)-1*H*-tetrazol-5-yl)methanol (3i)








1-(1-(2-bromobenzyl)-1*H*-tetrazol-5-yl)-2-methylpropan-1-ol (3j**)**








1-(1-(*tert*-butyl)-1*H*-tetrazol-5-yl)-3-phenylpropan-1-ol (3k)









1-(1-benzyl-1*H*-tetrazol-5-yl)propan-1-ol (3l**)**








1-(1-benzyl-1*H*-tetrazol-5-yl)-3-methylbutan-1-ol (3m)








1-(1-(*tert*-butyl)-1*H*-tetrazol-5-yl)-2-phenylethanol (3n**)**








(1-(*tert*-butyl)-1*H*-tetrazol-5-yl)(phenyl)methanol (3o**)**








(1-benzyl-1*H*-tetrazol-5-yl)(2,6-dichlorophenyl)methanol (3p)








(1-cyclohexyl-1*H*-tetrazol-5-yl)(2,3-dichlorophenyl)methanol (3q**)**








(5-bromo-2-methoxyphenyl)(1-phenethyl-1*H*-tetrazol-5-yl)methanol (3r)








(2-bromophenyl)(1-cyclohexyl-1*H*-tetrazol-5-yl)methanol (3s)








(2-chloro-3,4-dimethoxyphenyl)(1-cyclohexyl-1*H*-tetrazol-5-yl)methanol (3t**)**








(1-cyclohexyl-1*H*-tetrazol-5-yl)(6-nitrobenzo[*d*][1,3]dioxol-5-yl)methanol (3u**)**








(1-cyclohexyl-1*H*-tetrazol-5-yl)(2,5-dimethoxyphenyl)methanol (3v)








1-(1-benzyl-1*H*-tetrazol-5-yl)cyclohexanol (3w**)**





1-benzyl-4-(1-benzyl-1*H*-tetrazol-5-yl)piperidin-4-ol (3x)





5,11-dihydrobenzo[*f*]tetrazolo[5,1-*c*][1,4]oxazepine (4)

